Successful engraftment of a second transplant using non-myeloablative conditioning as treatment for graft failure following unrelated donor BMT

Bone Marrow Transplantation

Volumn 27, Issue 5, 2001, Pages 547-549

  Byrne, J L ^a   Musuka, C ^a   Davy, B ^a   Donovan, L ^a   Russell, N H ^a  

^a NOTTINGHAM CITY HOSPITAL   (United Kingdom)

Author keywords

Graft failure; MUD BMT; Non myeloablative conditioning; Second transplant

Indexed keywords

ALEMTUZUMAB; ALPHA INTERFERON; ANTIBIOTIC AGENT; BCR ABL PROTEIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTARABINE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; HYDROXYUREA; METHOTREXATE; MYELOABLATIVE AGENT; OPIATE; THYMOCYTE ANTIBODY;

ADULT; ALLOGRAFT; ARTICLE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CONDITIONING; CRYOPRESERVATION; CYTOGENETICS; DONOR; DRUG MEGADOSE; GRAFT VERSUS HOST REACTION; HEMATOLOGY; HLA MATCHING; HUMAN; LEUKAPHERESIS; LEUKEMIA REMISSION; MALE; MORTALITY; MUCOSA INFLAMMATION; NEUTROPENIA; PHILADELPHIA 1 CHROMOSOME; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; BONE MARROW TRANSPLANTATION; GRAFT REJECTION; GRAFT SURVIVAL; HISTOCOMPATIBILITY; HUMANS; LEUKEMIA, MYELOID, CHRONIC; MALE; REOPERATION; TRANSPLANTATION CONDITIONING;

EID: 0035068595     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702825     Document Type: Article

References (15)

1. Retrospective analysis of 462 unrelated marrow transplants facilitated by the National Marrow Donor Program for the treatment of acquired and congenital disorders of the lymphohematopoietic system and congenital metabolic disorders
2. Successful allogeneic transplantation of T-cell depleted bone marrow from closely HLA-matched unrelated donors
3. Unrelated donor marrow transplantation for chronic myelogenous leukemia: 9 years experience of the National Marrow Donor Program
4. Marrow transplantation from related donors other than HLA-identical siblings
5. Successful bone marrow transplantation with partially matched unrelated donors
6. Factors associated with graft rejection after HLA-identical marrow transplantation for aplastic anemia
7. Effects of in vitro depletion of T cells in HLA-identical allogeneic marrow grafts
8. Second allogeneic bone marrow transplants from unrelated donors for graft failure following initial unrelated donor bone marrow transplantation
9. Second HLA-identical sibling transplants for leukemic recurrence
10. Use of granulocyte colony stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: Comparison with cytarabine without granulocyte colony stimulating factor
11. The effect of the serotherapy regimen used and the marrow cell dose received on rejection, graft-versus-host disease and outcome following unrelated donor transplantation for leukaemia
12. Use of cryopreserved bone marrow in allogeneic bone marrow transplantation
13. Outcome of autologous rescue after failed engraftment of allogeneic marrow
14. Booster marrow or blood cells for graft failure after allogeneic bone marrow transplantation
15. Fludarabine based conditioning ('mini-transplant') for second allograft in acute leukaemia